Sharifi Mohsen, Fares Wassim, Abdel-Karim Isam, Koch J Michael, Sopko Joseph, Adler Dale
Department of Cardiology, St. Vincent Charity Hospital, Case Western Reserve University and the University Hospital of Cleveland, Ohio, USA.
Am J Cardiol. 2004 Jun 15;93(12):1533-5. doi: 10.1016/j.amjcard.2004.03.009.
The purpose of this trial was to assess whether the addition of hyperbaric oxygen to percutaneous coronary intervention can reduce clinical restenosis. Major adverse cardiac events at 8 months were found in only 1 of 24 patients (4%) who received hyperbaric oxygen compared with 13 of 37 patients (35%) who did not.
该试验的目的是评估在经皮冠状动脉介入治疗中添加高压氧是否能减少临床再狭窄。在接受高压氧治疗的24例患者中,仅有1例(4%)在8个月时发生主要不良心脏事件,而未接受高压氧治疗的37例患者中有13例(35%)发生该情况。